<DOC>
	<DOCNO>NCT01308723</DOCNO>
	<brief_summary>This open-label study ass safety , efficacy pharmacokinetics RO5323441 combination sorafenib patient advance metastatic hepatocellular carcinoma previously untreated systemic therapy . In dose-finding Part I , cohorts patient receive escalate dos RO5323441 intravenously ( iv ) every 2 week combination sorafenib 400 mg orally twice daily . In exploratory Part II , patient randomize receive either previously establish dose RO5323441 iv every 2 week plus continuous oral sorafenib sorafenib alone . Anticipated time study treatment disease progression unacceptable toxicity occur . For patient sorafenib arm disease progression crossover combination treatment RO5323441 allow .</brief_summary>
	<brief_title>A Dose-Finding Exploratory Study RO5323441 Combination With Sorafenib Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult patient &gt; /= 21 year age Advanced metastatic and/or unresectable hepatocellular carcinoma At least 1 measurable lesion accord RECIST criterion Primary tumor situ ( Expansion Cohort Part I , Part II ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate bone marrow , liver renal function Prior systemic treatment metastatic hepatocellular carcinoma patient tumor remove ( Expansion Cohort Part I , Part II ) Major surgery within previous 4 week plan major surgical procedure course study Radiation therapy within 28 day prior start study treatment Serious nonhealing wound , ulcer ore bone fracture History uncontrolled seizure encephalopathy within last 6 month Current central nervous system ( CNS ) metastases spinal cord compression History gastrointestinal perforation esophageal/gastric bleed within 6 month prior study enrollment History another primary malignancy treatment &lt; /= 3 year , except nonmelanoma skin cancer carcinoma situ cervix Patients prior liver transplant Inadequately control hypertension prior history hypertensive crisis hypertensive encephalopathy Active bleeding diathesis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>